Title

Accelerating the development and uptake of the most needed drug formulations for children

Code

MOSA18

Session Type

Non-Commercial Satellite

Venue

Hall 11B

Date Time

Monday 23 July, 10:15 - 12:15

Co-Chairs:

Martina Penazzato, World Health Organization (WHO), Switzerland
Paul Domanico, Clinton Health Access Initiative, United States

Organizer:

Global Accelerator for Paediatric Formulations (GAP-f - www.gap-f.org)

Limited treatment options and sub-optimal formulations contribute to poor adherence and outcomes for children living with HIV and other diseases that affect the lives of children living in resource-limited settings. The Global Accelerator for Paediatric Formulations (GAP-f) aims to promote a faster, more efficient and more focused approach to paediatric formulation development. This session will present key principles for acceleration – and how these are brought together by the GAP-f – for different areas of the continuum, with a focus on: (1) prioritization and clinical research of priority formulations, (2) development and regulatory approval of paediatric drug formulations, and (3) uptake and procurement of optimal formulations for children. Panels will discuss (1) the value and opportunities for an integrated approach to paediatric medicines and (2) the business case and innovative funding. The session will end with an overview of what to watch in paediatric drug optimization.

10:15 MOSA1801	Welcome Sébastien Morin, International AIDS Society, Switzerland	Slides

10:35 MOSA1802	Introduction: How can we accelerate the development and uptake of the most needed drug formulations for children? Charles Lyons, Elizabeth Glazer Pediatric AIDS Foundation, United States Linda-Gail Bekker, Desmond Tutu HIV Centre, South Africa Deborah Birx, The U.S. President's Emergency Plan for AIDS Relief (PEPFAR), United States

10:45 MOSA1803	Lived experience testimony: What non optimal paediatric drug formulations meant to me Sharifah Kyomukama Nalugo, Stigmaless Uganda, Uganda

10:50 MOSA1804	Acceleration part 1: Prioritization and clinical research of priority formulations Elaine J. Abrams, ICAP at Columbia University, United States Carlo Giaquinto, PENTA-Id Network, Italy	Slides

11:05 MOSA1805	Acceleration part 2: Development and regulatory approval of paediatric drug formulations Melynda Watkins, Clinton Health Access Initiative, United States Fernando Pascual, Medicines Patent Pool, Spain	Slides

11:20 MOSA1806	Acceleration part 3: Uptake and procurement of optimal formulations for children Nandita Sugandhi, ICAP at Colombia University, United States Jennifer Cohn, Elizabeth Glaser Pediatric AIDS Foundation, Switzerland	Slides

11:35 MOSA1807	Q&A Sébastien Morin, International AIDS Society, Switzerland Sharifah Kyomukama Nalugo, Stigmaless Uganda, Uganda Elaine J. Abrams, ICAP at Columbia University, United States Carlo Giaquinto, PENTA-Id Network, Italy Melynda Watkins, Clinton Health Access Initiative, United States Fernando Pascual, Medicines Patent Pool, Spain Nandita Sugandhi, ICAP at Colombia University, United States Jennifer Cohn, Elizabeth Glaser Pediatric AIDS Foundation, Switzerland	Slides

11:45 MOSA1808	Bringing it all together: The Global Accelerator for Paediatric Formulations (GAP-f) Martina Penazzato, World Health Organization (WHO), Switzerland Paul Domanico, Clinton Health Access Initiative, United States	Slides

12:00 MOSA1809	Panel discussion: Moving beyond HIV and planning the next steps Martina Penazzato, World Health Organization (WHO), Switzerland Paul Domanico, Clinton Health Access Initiative, United States Wiweka Kaszubska, Medicines for Malaria Venture, Switzerland Isabelle Andrieux-Meyer, Drugs for Neglected Diseases initiative, Switzerland George Siberry, US Department of State, United States Robert Matiru, UNITAID, Switzerland Taryn Barker, Children's Investment Fund Foundation, United Kingdom

12:30 MOSA1810	Summary and what to watch in paediatric drug optimization Robert Matiru, UNITAID, Switzerland Gottfried Hirnschall, World Health Organization (WHO), Switzerland	Slides